Cipla is an API and finished-dose manufacturer based in India. It holds 161 active US drug master files and 272 valid CEPs. Its filings concentrate with SAHPRA (ZA), US FDA and ARCSA (EC). Its GMP standing is certified by EMA, CDSCO (India) and ANVISA (Brazil), among 12 authorities. Its most recent recorded inspection, by US FDA, closed on 30 May 2025 as VAI. Customs aggregates show $1.0B of exports covering 18,463 molecules to 132 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Indore, United Arab Emirates | Not on file |
| Verna, United Arab Emirates | Not on file |
| Baddi, Colombia | Not on file |
| Verna, Colombia | Not on file |
| ADDLESTONE, United Kingdom | Not on file |
| Bengaluru, India | 3005857289 |
6 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Fluticasone Propionate | EDQM, SFDA (Saudi Arabia), US FDA | 21 |
| Omeprazole | EDQM, SFDA (Saudi Arabia), US FDA | 16 |
| Mometasone Furoate | EDQM, SFDA (Saudi Arabia), US FDA | 12 |
| Amlodipine | EDQM, SFDA (Saudi Arabia), US FDA | 10 |
| Budesonide | EDQM, SFDA (Saudi Arabia), US FDA | 10 |
| Salbutamol Sulfate | EDQM | 8 |
| Venlafaxine Hydrochloride | EDQM | 8 |
| Celecoxib | EDQM, SFDA (Saudi Arabia), US FDA | 7 |
| Albuterol | EDQM, US FDA | 6 |
| Escitalopram | EDQM, US FDA | 6 |
| Esomeprazole | EDQM, US FDA | 6 |
| Etoposide | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Finasteride | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Fluconazole | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Granisetron | EDQM, US FDA | 6 |
| Letrozole | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Meloxicam | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Ondansetron | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Pantoprazole | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Risperidone | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Rivastigmine | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Sorafenib | EDQM, US FDA | 6 |
| Carvedilol | EDQM, SFDA (Saudi Arabia) | 5 |
| Citalopram | EDQM, US FDA | 5 |
| Entecavir | EDQM, US FDA | 5 |
| Exemestane | EDQM, US FDA | 5 |
| Felodipine | EDQM, US FDA | 5 |
| Formoterol | EDQM, US FDA | 5 |
| Gefitinib | EDQM, US FDA | 5 |
| Lamivudine | EDQM, US FDA | 5 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| SAHPRA (ZA) | 912 | 3 |
| US FDA | 314 | 5 |
| ARCSA (EC) | 180 | None |
| DIGEMAPS (DO) | 143 | None |
| EMA | 103 | 20 |
| ZAMRA (ZM) | 84 | None |
| CDSCO (India) | None | 19 |
| ANVISA (Brazil) | None | 6 |
| MHRA (UK) | None | 5 |
| TMDA (TZ) | None | 3 |
| NAFDAC (NG) | None | 3 |
| FDA (GH) | None | 2 |
| MFDS (Korea) | None | 2 |
| NCELS (KZ) | None | 1 |
| INVIMA (CO) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $118.8M | 81 |
| 2025 | $3.2B | $1.0B | 132 |
| 2024 | $3.1B | $744.1M | 127 |
| 2023 | $2.8B | $766.9M | 135 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Cipla comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.